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The objective of this study was to evaluate the maximum tolerated dose (MTD) and recommended dose of irinotecan administered
as a 5-day schedule synchronously with 5-fluorouracil (5FU), leucovorin (LV) and preoperative pelvic radiation (45Gy) for primary
borderline/unresectable, locally advanced rectal cancer. The study used escalating doses of intravenous irinotecan (6, 8, 10, 12, 14, 16,
18, and 20mgm
 2) administered on days 1–5 and 29–33 followed by low dose LV (20mgm
 2) and 5FU (350mgm
 2 over 1h) in
sequential cohorts. Preoperative pelvic radiotherapy using a three- or four-field technique and megavoltage photons comprised
45Gy given in 25 fractions, 1.8Gy per fraction. Surgery in the form of mesorectal excision was performed 6–10 weeks later.
Histopathological examination of the resected specimen was performed according to techniques of Quirke, and compared with
clinical staging. A distance of 1mm or less between the peripheral extent of the tumour and the radial resection margin defined an
involved circumferential resection margin (CRM). The MTD was determined as the dose causing more than a third of patients to
have a dose-limiting toxicity (DLT) defined as specific grade 3 or 4 toxicities. Once the MTD was reached, a further 14 patients were
treated at the dose level below the MTD. In total, 57 patients received irinotecan at the eight dose levels. The final cohort reached
DLT after only four patients had been enrolled. The median age was 62 years (range 26–75), 37 male and 20 female subjects. The
MTD of irinotecan in this schedule was 20mgm
 2 when three out of four patients experienced DLT. Dose limiting grade 3 or 4
diarrhoea was reported in seven out of 57 patients, three at the 20mgm
 2 dose level. Serious haematological toxicity (grade 3) was
minimal and reported in only three patients; one grade 3 neutropaenia, one grade 4 neutropaenia and one grade 3 febrile
neutropaenia and anaemia. Compliance was good with 93 and 89% of patients completing radiotherapy and chemotherapy,
respectively. The remaining patients had only minor deviations from protocol therapy. Eight patients did not proceed to surgery, in six
cases because they remained unresectable or had developed metastatic disease, one patient was unfit for surgery and one died as a
result of complications from radiotherapy. Forty-nine patients underwent a potentially curative surgical resection. Histopathological
examination of the resected specimen demonstrated pCR 12 out of 49 (24%) and 12 out of 57 (21%) overall. A histologically
confirmed clear circumferential resection margin (CRM) was achieved in 39 out of 49 (80%) of those resected, and 39 out of 57
(68%) overall. In conclusion, MTD with this scheduled regimen of irinotecan is 20mgm
 2 (days 1–5 and 29–33). The acceptable
toxicity and compliance at 18mgm
 2 recommend testing this dose in future phase III studies. The tumour downstaging and complete
resection rates (negative CRM) are encouragingly high for this very locally advanced group.
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A curative surgical resection remains the most important
component of the modern multimodality management of rectal
cancer. However, randomised controlled trials (Swedish Rectal
Cancer Trial, 1997; Kapiteijn et al, 2001; Sauer et al, 2004) and two
meta-analyses (Camma ` et al, 2000; Colorectal Cancer Collaborative
Group, 2001) have demonstrated that in clinically resectable rectal
cancer, preoperative adjuvant radiation or chemoradiation can
reduce the rate of locoregional recurrence, although its impact on
overall survival is less clear.
Recent advances which have contributed to an improved
outcome in rectal cancer include a more radical surgical technique
incorporating mesorectal excision (TME) (Enker et al, 1995; Heald
et al, 1998) and a more accurate histopathological examination of
the resected specimen reporting the proximity of microscopic
tumour to the circumferential resection margin (CRM) (Quirke
et al, 1986). Individual surgical series, a population-based audit
(Wibe et al, 2002) and evidence from a randomised controlled trial
(Nagtegaal et al, 2002) all demonstrate lower rates of local
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srecurrence following TME compared with the previous rando-
mised trials that included a surgery alone arm. In addition,
involvement of the circumferential resection margin is associated
with a significantly increased risk of both local recurrence and also
metastatic disease.
Preoperative chemoradiation (CRT) is increasingly used in
patients with more locally advanced, borderline and unresectable
rectal cancer, despite the fact that there are few trials in the
modern era that have compared preoperative CRT with radiation
alone (Frykholm et al, 2001). The aims of treatment are to reduce
the extent of the primary tumour to allow macroscopic removal to
take place, to treat potential microscopic disease close to or
beyond the mesorectal fascia and if present also to treat micro-
metastatic disease outside the radiation fields. Most current CRT
schedules combine pelvic radiation with either continuous
infusion of 5-fluorouracil (5FU), or 5FU modulated by LV. Mature
results from the EORTC 22921 and FFCD 9203 trials of operable
T3/T4 rectal cancer have recently demonstrated a convincing
reduction in locoregional failure when a CRT regimen of 5FU and
LV is added to 45Gy of pelvic radiation over radiotherapy alone
(Bosset et al, 2005a,b; Gerard et al, 2005). As the EORTC 22921
and FFCD 9203 trials used daily 5FU LV based CRT schedules, at
the time the present study was designed, it was a logical step to
develop preoperative radiation schedules that incorporated the
addition of irinotecan to the same regimen. The choice of the 5FU
LV regimen required the 5-day schedule of irinotecan to be given
in weeks 1 and 5 to ensure concomitant administration.
Preclinical studies have demonstrated irinotecan to be a potent
radio-sensitising agent in human lung tumour xenografts (Tamura
et al, 1997) and colorectal cancer (Wang et al, 1996; Omura et al,
1997; Chen et al, 1999), even under hypoxic conditions, which
normally render tumours radio-resistant (Boscia et al, 1993). The
mechanism of this interaction may reflect the attachment of the
DNA-topoisomerase I adducts at sites of DNA single-strand
breaks, or radiation-induced synchronization of the tumour cell
population in the S phase of the cell cycle, where cells are more
sensitive to irinotecan chemotherapy (Falk and Smith, 1992).
Furthermore, the cytotoxic effects of camptothecins are highly
schedule dependent. Both 5FU (Byfield et al, 1982) and irinotecan
(Kirichenko et al, 1997) are radiation sensitisers, which appear
both dose and schedule dependent according to preclinical models.
In the preclinical setting, more frequent fractionated schedules
appear more effective (Kirichenko and Rich, 1999). This hypo-
thesis, to some extent, is logical if one considers that the half-life of
SN38 (the metabolite of the camptothecins) is long, and a daily
intravenous schedule can result in a relatively steady level.
Radiation sensitisation occurs during or after irradiation (Omura
et al, 1997). Hence, we have used a protracted low-dose schedule of
irinotecan in the present study.
The rationale behind the use of these two drugs combined with
radiotherapy lies in the evidence from phase III trials in metastatic
colorectal cancer, which have demonstrated statistically significant
improvements in overall response rate and median time to
progression and overall survival when the topoisomerase-I
inhibitor irinotecan is added to a combination of 5FU and LV
(Douillard et al, 2000; Saltz et al, 2000). It is also recognised that
20–40% of rectal cancer patients continue to develop distant
metastases and die despite the optimal use of TME and a very low
risk of local recurrence (Kapiteijn et al, 2001; Sauer et al, 2004).
Also a recent review of phase II and III trials of preoperative
chemoradiotherapy (Hartley et al, 2005) showed that on multi-
variate analysis only the mode of delivery of 5FU (infusion rather
than bolus), the use of a second drug in addition to 5FU and the
total radiation dose were associated with a higher rate of
pathological complete response.
The present study aimed to evaluate the toxicity and efficacy of
the addition of a 5-day schedule of irinotecan to a regimen of
chemoradiation that uses 5FU and LV daily during the first and
fifth weeks of pelvic radiation (45Gy) as used in the EORTC 22921
and FFCD 9203 phase III trials (Bosset et al, 2005a,b; Gerard et al,
2005).
PATIENTS AND METHODS
Study design
This dose escalation study aimed to increase the dose of irinotecan
given on days 1–5 and 29–33 in successive cohorts when added to
a chemoradiation (CRT) regimen consisting of low-dose LV and a
short infusion of 5FU administered concurrently with radiation
until the maximum tumour dose was reached. All patients received
radiotherapy (45Gy) with LV (20mgm
 2) and 5FU (350mgm
 2
administered over 1h) on days 1–5 and 29–33, see Figure 1.
Escalating doses of 2mgm
 2 were given starting at 6mgm
 2 in
three patients. Subsequent cohorts consisted of six patients.
Irinotecan was administered in 100ml normal saline or dextrose
over 2h given on days 1–5 and 29–33 (6, 8, 10, 12, 14, 16, 18 and
20mgm
 2) before the LV and 5FU. Dose-limiting toxicities were
defined to include grade 3 or 4 diarrhoea, mucositis, grade 3 or 4
thrombocytopaenia and grade 4 neutropaenia associated with fever
or lasting for more than 7 days according to the National Cancer
Institute Canada common toxicity criteria revised 1994 definitions.
Toxicity was recorded prospectively, weekly up to week 6 and then
at week 10.
If Grade III or IV dose-limiting toxicity was observed in two or
less patients in a cohort of six, then a further cohort were treated at
the next dose level. The maximum tolerated dose (MTD) was
defined if three or more of six patients experienced dose-limiting
Irintotecan
20 mg m–2
18 mg m–2
16 mg m–2
14 mg m–2
12 mg m–2
10 mg m–2
8 mg m–2
6 mg m–2
Radiotherapy–3/4 field planned volume 45 Gy in 25 fractions
↓↓ ↓↓↓ ↓↓ ↓↓↓ ↓↓ ↓↓↓ ↓↓ ↓↓↓ ↓↓ ↓↓↓
Figure 1 Chemoradiation schedule. & Irintotecan at dose levels shown on days 1–5 and 29–33 prior to LV, 5FU; Leucovorin 20mgm
 2 bolus days
1–5, 29–33; 5FU 350mgm
 2 60min infusion days 1–5, 29–33; k radiotherapy 1.8Gy per fraction.
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stoxicity (DLT). Once the MTD was defined, the preceding dose
level would then be expanded and a total of 20 patients were
treated at the recommended dose.
The primary end points of the study were to determine the MTD
of irinotecan. Secondary end points included acute toxicity,
compliance with the planned doses of chemotherapy and radio-
therapy, and efficacy. Efficacy was measured using the following:
histopathological complete response rate, complete resection rate
and local recurrence rate.
Eligibility criteria
Eligibility criteria included histologically confirmed adenocarci-
noma, WHO performance status 0–2 and no evidence of
metastatic disease using chest X-ray and abdomino-pelvic CT.
Acceptable haematological and renal function was required:
neutrophils 41.5 10
9l
 1, platelets X100 10
9l
 1 and serum
creatinine o1.25  the institutions upper limit of normal range.
Patients with locally advanced, biopsy proven carcinoma of the
rectum were included either on the basis of fixity on digital rectal
examination (DRE), T4 stage on pelvic CT or when MRI
demonstrated a high risk of involvement of the circumferential
resection margin. The method used to define locally advanced
disease, distance of inferior tumour border to the anal verge (cm)
and intended surgical procedure were also recorded.
Patients were excluded from the study because of prior
chemotherapy or pelvic radiation, lack of efficient contraception
or pregnancy and bowel or cardiac conditions that would deter the
safe delivery of 5FU. Patients having six episodes of stool per day
or who were incontinent of faeces were also excluded.
Pelvic radiation
Using information from clinical examination and pelvic MRI, the
gross tumour volume (GTV) was defined using a CT planning
scan. Alternatively, orthogonal film simulation was performed with
opacification of the small bowel using barium sulphate 300ml with
gastrograffin 20ml. To derive a planning target volume (PTV)
margins were added to the GTV according to the radiation
planning diagrams (3cm laterally and inferiorly, 2cm anteriorly
and superiorly) included in the protocol with the exception of the
posterior border, which was always located on the most posterior
aspect of the bony sacrum. Patients were treated prone with a full
bladder using either a three- or four-field technique. A total dose
of 45Gy was delivered to the International Commission on
Radiation Units intersection point using 25 daily fractions of
1.8Gy.
Surgery and histopathology
Surgery was recommended to take place 6–10 weeks after
completion of chemoradiation. Histopathological examination
of the resected specimen was performed according the technique
described by Birbeck and Quirke (1999). The circumferential
resection margin is considered involved, if microscopic tumour
(due to any cause) is present at or less than 1mm from the
circumferential or radial resection margin.
Assessment during and after treatment
Full blood count, urea creatinine and electrolytes and liver
function tests and acute toxicity scores were assessed prospectively
on weeks 1–6 and 10. On completion of CRT, follow-up
appointments were given at 3, 6 12, 24 and 36 months to assess
tumour recurrence and late toxicity.
For the purposes of this study, local recurrence has been defined
in patients who have had a complete macroscopic resection as
evidence of either an intraluminal or extraluminal mass below the
sacral promontory and biopsy proven adenocarcinoma or CEA
abnormal with or without the presence of metastases. Radiological
evidence of interval enlargement of the mass (minimum interval of
6 weeks) was required if based on CT scans alone (biopsy negative
and CEA normal).
RESULTS
Between June 2000 and May 2005, a total of 59 patients were
recruited from four centres. Two patients were excluded; one
patient stopped chemotherapy owing to 5FU-induced chest pain,
and the second patient represented a protocol deviation because
they received bolus 5FU instead of infusional 5FU. The character-
istics of the 57 eligible patients are summarised in Table 1.
Protocol compliance
Protocol compliance was good, although one patient progressed
during treatment and stopped their radiotherapy and chemo-
therapy early. Radiotherapy was minimally reduced (one fraction
not given) in three patients owing to side effects (pain, illness and
diarrhoea), all other patients received the full radiotherapy dose.
Only five patients failed to receive all planned chemotherapy,
which was reduced in four cases due to toxicity; pain (one),
diarrhoea (two) and weight loss (one). The remaining patient
fainted prior to treatment and that day’s chemotherapy treatment
was omitted.
The median field size, in all patients, for the posterior/anterior
field was 15.2cm (range 9.8–20.5) length 14.0cm (range 9.9–
18.1) PA width, and for the lateral/oblique fields 15.1cm (range
9.8–20.5) height 13.0cm (range 9.9–17.7) AP field size on
lateral. Forty-nine out of 57 patients proceeded to have radical
surgery, with a median interval to surgery of 10 weeks (IQR 7–12
weeks).
Acute toxicity
The acute grade 3/4 toxicity experienced is summarised for the
eight dose levels and the subsequent patients treated in the
expanded cohort at 18mgm
 2 in Table 2. During the dose
escalation phase, DLT was seen in three out of four patients at
20mgm
 2. In view of this toxicity, the decision was made to stop
recruitment to this dose level and to expand the18mgm
 2 dose
level to the planned total of 20 patients.
The most common toxicity was grade 3 diarrhoea, this occurred
in seven patients. Haematological toxicity was uncommon with
only three patients affected; grade 3 neutropaenia (14mgm
 2),
grade 4 neutropaenia (18mgm
 2) and grade 3 febrile neutropaenia
Table 1 Patient and tumour characteristics
Characteristic n¼57
Median age (range) 62 (26–75)
Male:female 37:20
WHO status 0:1:2 39:16:2
Site of tumour
Upper:mid:lower 8:18:31
Local extent
Fixed/unresectable 23
Locally advanced on MRI 33
a
Increase chance of sphincter preservation 1
aIncludes three patients with partially fixed unresctable disease also. WHO¼World
Health Organisation; MRI¼magnetic resonance imaging.
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sand grade 3 anaemia (8mgm
 2). One patient died 2 weeks after
chemoradiation of complications following radiation ileitis.
Response to treatment
Tumour downstaging was defined by comparing clinical TN stage
prior to treatment (as determined by pelvic MRI) with histopatho-
logical stage post surgery. Chemoradiation therapy achieved
downstaging in 20 out of 49 (41%) of patients. The pathological
stages at surgery were ypT0N0¼12, ypT1NO¼1, ypT0N1¼1,
ypT1N1¼0, ypT2N0¼7, ypT2N1¼2, ypT3N0¼14, ypT3N1¼4,
ypT3N2¼2 and ypT4N0¼2, ypT4N1¼3, ypT4N2¼1. It can be
seen that CRT achieved a complete pathological response in 12 out
of 49 (25%) of cases who proceeded to surgery (Table 3) and 12 out
of 57 (21%) of the whole group. Histopathology also demonstrated
microscopic disease only (Tmic) in two out of 49 (4%) patients,
pCRþ Tmic in 14 out of 49 (29%), pT0-2 in 20 out of 49 (41%)
and histologically confirmed (41mm) clear circumferential
resection margins (CRM) in 41 out of 49 (84%) of those resected,
and 39 out of 57 (68%) overall.
Surgery
Of the 57 evaluable patients, eight did not proceed to surgery,
in six cases because they remained unresectable (two) or had
metastatic disease (four), one patient was unfit for surgery and
one died as a result of complications from radiotherapy (Figure 2).
All patients had a preliminary clinical assessment by their surgeon
Table 2 Acute toxicity
Irintotecan dose (mgm
 2) 6 8 1 01 21 41 6 1 8
a 20 All
No. of patients 3 6 66666/14 4 57
Patients with DLT 0020101 /   37
Gd 3 diarrhoea — — 2 — 1 — 1/  37
Gd 3 neutropaenia — — — — 1 —  /  —1
Gd 4 neutropaenia — — ———— /1 — 1
Gd 3 febrile neut — 1 ———— /  —1
Gd3 anaemia — 1 ———— /  —1
Gd 3 nausea — — — — 1 — 1/  —2
Gd 3 vomiting — — 1 — 1 — 1/  —3
Gd 3radiation derm — — 1 — — —  /  —1
Gd 4 rash/desq — — ———— 1 /   —1
Gd 3 pain — — — — 1 —  /1 — 2
Gd 4 pain — — ———— 1 /   —1
Gd 3 constipation — — ———— /1 — 1
aThe figures in this column indicate the numbers in the initial six patients treated at this dose level followed by the numbers in the expanded group once the MDT was
determined. DLT¼dose-limiting toxicity.
Table 3 Pathological response
Irintotecan dose (mgm
 2)681 01 21 41 61 8
a 20 All (%)
Number of patients 3 6 6 6 6 6 6/14 4 57
Number operated 3 5 6 5 5 5 5/12 3 49/57 (86%)
pCR 1 0 1 1 1 1 3/3 1 12/49 (25%)
Tmic 0 0 0 0 0 0 1/0 1 2/49 (4%)
RO (–ve CRM)
b 3 3 6 4 5 4 5/8 3 41/49 (84%)
pT0-2 pN0 2 0 3 1 2 1 4/5 2 20/49 (41%)
aThe figures in this column indicate the numbers in the initial six patients treated at this dose level followed by the numbers in the expanded group once the MDT was
determined.
b ve CRM¼tumour clearance of more than 1mm from circumferential resection margin; pCR¼histopathological complete response; Tmic¼microscopic disease
only detected in surgical specimen; CRM¼circumferential resection margin.
Alive with disease 1 
Cancer death 6 
Radiation related death 1 
Potentially curative resection
n=49
No resection   
n=8
CRM –ve (R0) 
n=41
Alive disease free 28
Alive with disease 4 (4 DR) 
Cancer death 8 (2 LR, 4 DR) 
Non cancer death 1 (DF)
Evaluable patients*
n=57
CRM +ve (R1) 
n=8
Alive disease free 1 
Alive with disease 2 (1 LR, 1DR) 
Cancer death 5 (3 LR, 2 LR and DR)
Figure 2 Patient outcome. *Two unassessable patients not included; one patient discontinued chemotherapy owing to chest pain and the other had
bolus 5FU on day 1. LR¼locoregional recurrence, DR¼distant recurrence, DF¼disease free.
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sat entry and were categorised on the basis of height of the cancer
from the anal verge as requiring an abdomino-perineal resection
(APER), anterior resection (AR) or pelvic clearance (PC).
Of the 49 radical surgical procedures, 24 had an APER, 20
patients an AR, one patient had a low Hartmann’s operation. Three
female patients required APER and total abdominal hysterectomy
and bilateral salpingo-oopherectomy and a male patient had an AR
and removal of the bladder and prostate. There were no
unexpected postoperative complications or deaths.
Local recurrence and survival
The median follow-up is 16 months (range 0–60 months) for all
patients, 23 patients (40%) have follow-up of 2 years or more.
Thirty-seven of the 57 patients remain alive at the time of writing.
Of the 41 patients having complete surgical clearance of tumour
(CRM negative), 11 relapsed (one at local and distant sites and 10
distant sites only), of which seven subsequently died of disease
(Figure 2 and Table 4). Of the eight incomplete resections (CRM
positive), five patients have died, three are alive; two with disease
and one currently remains disease free. All but one of the eight
patients who were not resected have died, the remaining patient is
alive with disease. The disease-free survival (DFS) for the whole
group at 3 years is 40% (95% CI 24–55%) (see Figure 3) and 54%
(95% CI 32–72%) for those having had a complete resection.
Of the 20 patients who were downstaged to T0-2 NO, 15 remain
alive and disease free, two are alive with distant metastases and
three have died of distant disease. Of the 29 patients that were
not downstaged (T3/4 NO/1 or T0-2 N1 disease), 10 died due to
disease, 18 are alive; four with disease and 14 disease free. The
remaining patient died of a myocardial infarction but was disease
free at the time of death.
Late effects
Severe late effects were uncommon despite the combination of
irinotecan and radiotherapy with one patient reporting Grade 3
tenesmus at assessment 12 months after treatment, which later
improved to grade 1/2 and had resolved by 4 years.
DISCUSSION
The primary aim of our current treatment strategy in rectal cancer
is to ensure long-term local control, by achieving a curative
resection with a clear circumferential resection margin (41mm).
However, in many patients with more locally advanced disease, the
tumours often remain fixed and unresectable following CRT, and
others fail to achieve a histologically curative resection despite
neoadjuvant chemoradiation (Mawdsley et al, 2005). A number of
phase II studies using 5FU have reported high rates of PCR and
R0 resection even in advanced low rectal cancers. However, the
incidence of metastases remains unacceptably high for this group
of patients, and does not appear to be influenced by the addition of
5FU over radiation alone (Bosset et al, 2005a,b; Gerard et al, 2005).
Intensification of the neoadjuvant strategy has, therefore, been
tested in terms of the addition of further cytotoxic agents such as
oxaliplatin and irinotecan to standard 5FU-based chemoradiation
in an attempt to improve efficacy of downstaging, improve
resectability and eradicate potential micrometastases more effec-
tively. Irinotecan appears suitable for inclusion in a neoadjuvant
chemoradiation regimen based on the higher response rates
observed in randomised trials in metastatic disease (Douillard
et al, 2000; Saltz et al, 2000).
The MTD of a scheduled regimen of irinotecan combined with
low-dose LV and a 60min infusion of 5FU with 45Gy of pelvic
radiotherapy (using relatively large field sizes) given preopera-
tively in patients with locally advanced rectal cancer has been
defined in the present study as 20mgm
 2, days 1–5 and 29–33.
The recommended dose in this setting is 18mgm
 2. This overall
total dose of irinotecan (180mgm
 2) is similar to that achieved
by others using a schedule of 40–60mgm
 2 weekly during
radiotherapy (Levine et al, 2003; Mehta et al, 2003).
Compliance with treatment (93% radiotherapy and 89%
chemotherapy) in the present study compares favourably with
the EORTC 22921 study where compliance to RT was 96% and to
chemotherapy was only 71% (Bosset et al, 2004). In addition, the
rate of grade 3/4 diarrhoea in this study of 12% is lower than other
similar studies with a weekly regimen of irinotecan, which range
from 30 to 40% (Mitchell et al, 2001; Mehta et al, 2003; Klautke
et al, 2005).
The eligibility criteria used in this study define a relatively
homogeneous group of advanced borderline/unresectable rectal
cancer. A total of 23 out of 57 (40%) patients had tumours, which
were clinically fixed. The PCR rate of 21% in the present study is
high compared to CRT regimens, which use single agent 5FU or
capecitabine, and is similar to other reported irinotecan CRT
regimens (see Table 5).
The histologically confirmed RO (CRM  ve) resection rate of
83% for those resected and 68% overall is acceptable for studies in
this group of borderline unresectable rectal cancers (Wheeler et al,
2004; Mawdsley et al, 2005; Sebag-Montefiore et al, 2005). In the
present study, only two patients had disease, which remained fixed
and unresectable following CTRT, and only three patients had
partial pelvic clearances. In contrast, the German CAO/ARO/AIO
94 study (Rodel et al, 2003) reported eight out of 31 patients who
underwent exenteration or resection of adjacent organs.
Enthusiasm for preoperative chemoradiation in the manage-
ment of rectal cancer is increasing. The German CAO/ARO/AIO 94
study protocol has convincingly shown improved locoregional
control and reductions in acute and late toxicity with preoperative
Table 4 Pattern of recurrence following radical resection
Irintotecan dose
(mgm
 2) 6 8 1 01 21 41 61 82 0 A l l
Number of patients 3 5 6 5 5 5 5/12 3 49
Any disease 2 1 3 3 3 1 2/4 0 19 (39%)
Local recurrence 1 1 0 2 0 1 0/3 0 8 (16%)
Distant metastases 2 1 3 1 3 1 2/1 0 14 (29%)
Cancer death 2 1 2 3 2 1 0/2 0 13 (27%)
Other death 0 0 0 0 0 1
a 0/0 0 1 (2%)
aCardiac death, no cancer present at time of death.
Kaplan–Meier survival estimate
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Figure 3 Disease-free survival – all patients.
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schemoradiation (Sauer et al, 2004) versus postoperative combined
modality treatment for stage II/III resectable rectal cancer.
There is considerable enthusiasm for integrating irinotecan into
preoperative combined regimens in rectal cancer, and there have
been several reported phase I and II studies (Levine et al, 2003;
Mehta et al, 2003; Mitchell et al, 2003; Klautke et al, 2004). Most
investigators have explored weekly schedules of irinotecan with
infusional 5FU in combination with pelvic radiotherapy (Mitchell
et al, 2001; Navarro et al, 2006).
The first study was performed by Mitchell in 2001; as with other
studies, high initial PCR rates have not been confirmed with a
larger number of patients (Mitchell et al, 2003). An update of this
study (Kim et al, 2005) suggests that the pCR rate may be much
higher for small tumourso 5cm. They showed that 11 out of 28
(39%) of small tumours achieved PCR, compared to only five out
of 30 (17%) of tumours larger than 5cm. Final recommendations
from the results of this study were to use 250mgm
 2 per day of
5FU by continuous infusion, and 50mgm
 2 weekly of irinotecan
combined with a radiation dose of 54Gy. This regimen has been
formally compared with a twice-daily hyperfractionated regimen
in a randomised phase II study under aegis of the RTOG (RTOG
R-0012). UK investigators have explored similar schedules (Levine
et al, 2003) and produced a recommended dose of 5FU by
continuous infusion 200mgm
 2 and irinotecan 60mgm
 2 weekly
with 45Gy of radiotherapy.
Further investigators have also combined capecitabine and
irinotecan (Kennedy et al, 2004; Becerra et al, 2005; Gollins et al,
2005; Willeke et al, 2005). While preliminary, the current findings
indicate that combinations of capecitabine and weekly irinotecan
are feasible in this setting. Capecitabine doses can be up to
825mgm
 2 twice daily continuously, while irinotecan can be given
up to 60mgm
 2, if only four infusions are administered.
Currently, there is a further ongoing randomised phase II study
in the preoperative setting under the aegis of the RTOG (RTOG-
0247), which compares a combination of irinotecan and capeci-
tabine with a combination of oxaliplatin and capecitabine and
higher doses of radiotherapy (50.4Gy) than in the present study.
Similarly, Klautke et al (2005) also explored 50.4Gy with
continuous infusion 250mgm
 2 per day and irinotecan 40mgm
 2
weekly, and described an incidence of grade 3 diarrhoea of 35%.
This level of toxicity is probably unacceptable for a multicentre
phase III study despite a 26% pathological complete response. An
even higher complete response rate has been reported from Mehta
et al where again patients were treated with 50.4Gy conformal
radiotherapy and continuous infusion 5FU 200mgm
 2 per day
and 50mgm
 2 weekly 4 of irinotecan. This schedule also
provoked a high incidence of grade 3 diarrhoea (28%), although
there was an impressive 37% pCR rate.
In the preoperative treatment of rectal cancer, it remains
to be seen whether the rate of achieving a PCR is an independent
prognostic factor for survival. Few studies report long-term
local control, late toxicity or the subsequent incidence of
metastatic disease. We are continuing to follow this group of
patients and hope to provide better information on these issues
in the future. Nevertheless, the high levels of pathological complete
response with irinotecan need to be confirmed in randomised
studies, and the present 5-day schedule would be interesting
to assess in combination with capecitabine in phase III rando-
mised trials.
We have yet to determine the optimal irinotecan-based
preoperative chemoradiation regimen in rectal cancer. Phase I/II
trials confirm that the combination is feasible and highly effective,
but many of the studies have shown high levels of grade 3 toxicity
– in terms of diarrhoea, see Table 5.
The present study has a number of important differences from
the previously described studies (see Table 5). Firstly, the total
dose of radiation was fixed at 45Gy, a total dose that is 10% lower
than many of the other studies. This dose might be expected to be
associated with a lower incidence of late complications, and also a
lower rate of pathological complete response (Hartley et al, 2005).
Secondly, this study formally determined the MTD and recom-
mended dose of irinotecan when added to a validated CRT
fluoropyrimidine schedule used in a phase III trial (Bosset et al,
2005a,b). Finally, this study reports outcome data that is based
on the circumferential margin status. Now that there is clear
evidence that locoregional control is improved by the addition of
the 5FU/LV regimen used in this study to 45Gy of pelvic radiation
(Bosset et al, 2005a,b; Gerard et al, 2005), there is a strong
rationale for future trials to establish the benefit of the addition of
irinotecan.
These data suggest that combination radiochemotherapy leads
to improved early histopathological outcome measures. This has
the potential to translate into improved long-term outcomes in
rectal cancer, both in terms of quality of life and overall survival
and will be tested in current and future phase III trials.
CONCLUSION
The maximum tolerated dose of this scheduled regimen is
confirmed as 20mgm
 2, and the recommended dose of irinotecan
in BURC is 18mgm
 2given on days 1–5 and 29–33 when added to
5FU/LV and 45Gy of radiation preoperatively. We are continuing
to follow this group of patients and hope to provide better
information on long-term local control, late toxicity or the
subsequent incidence of metastatic disease in the future.
Table 5 Preoperative chemoradiation schedules using irinotecan
Study/year
No. of
patients Fluoro-pyrimidine Irinotecan schedule
RT
dose
(Gy)
G3/4
diarrhoea
(%)
PCR
(%)
Levine/2003 12 PVI:5FU 200mgm
 2, daily over 5 weeks 60mgm
 2 weekly 4 45.0 25 —
Mehta/2003 32 PVI:5FU 200mgm
 2, days 1–33 50mgm
 2 weekly 4 50.4 28 38
Mitchell/2003 67 PVI:5FU 225mgm
 2, 5 days a week 50mgm
 2 weekly 4 54.0 — 25
Klautke/2005 37 PVI:5-FU 250mgm
 2, days 1–43 40mg weekly 6 50.4 32 22
Navarro/2006 74 PVI:5FU 225mgm
 2, 5 days a week 50mgm
 2 weekly 5 45.0 14 14
Descartes/2006 57 5FU 350mgm
 2, LV (20mgm
 2, days 1–5 and 29–33 18mgm
 2 days 1–5 and 29–33 45.0 12 25
Hofheinz/2005 19 Capecitabine 500mgm
 2, b.i.d., days 1–38 50mgm
 2 weekly 5 50.4 16 21
Gollins/2006 40 Capecitabine 650mgm
 2, b.i.d., days 1–33 60mgm
 2 weekly 4 45.0 28 25
Klautke/2006a (BJC) 28 Capecitabine 750mgm
 2, b.i.d., days 1–43 40mg weekly 6 50.4+5.4 39 14
Klautke/2006b (ASCO) 20 Capecitabine 750mgm
 2, b.i.d., days 1–14, 22–35 50mg weekly 4 50.4+5.4 10 0
Klautke/2006b (ASCO) 11 Capecitabine 750mgm
 2, b.i.d., days 1–14, 22–35 60mg weekly 4 50.4+5.4 9 33
Mitchell/2006 16 Capecitabine, MTD not yet reached 50mgm
 2 weekly 4 50.4 or 54 — 23
PVI¼protracted venous infusion; RT¼radiotherapy; PCR¼polymerese chain reaction; MTD¼maximum tolerated dose; 5FU¼5-fluorouracil.
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